Shares in Natco Pharma surged 6 percent after prospects for its generic version for Teva Pharmaceutical Industries'billion dollar drug got a boost from a favourable U.S. court ruling on Wednesday.
A U.S. Supreme Court justice on Wednesday declined a request from Teva for a stay of an appeals court ruling that would strip the company's $4 billion-a-year multiple sclerosis drug Copaxone of patent protection in 2014, rather than in 2015.
In July, the U.S. Court of Appeals for the Federal Circuit issued a decision in a patent fight that pits Teva against two teams developing cheaper generic forms of Copaxone: one with Novartis AG and Momenta Pharmaceuticals Inc; and another between Mylan Inc and Natco Pharma.
Copyright @ Thomson Reuters 2013
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
